<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023230</url>
  </required_header>
  <id_info>
    <org_study_id>DV4-HBT-02</org_study_id>
    <secondary_id>2009-010142-66</secondary_id>
    <nct_id>NCT01023230</nct_id>
  </id_info>
  <brief_title>A Study to Assess DV-601 in Subjects With Chronic Hepatitis B</brief_title>
  <official_title>A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine
      will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and
      immunological responses in chronic hepatitis B (CHB) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient diaries, adverse events, physical exams, and lab tests</measure>
    <time_frame>Through Day 99</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV-DNA levels</measure>
    <time_frame>Change from baseline to Days 43 and 99, and to Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>DV-601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DV-601</intervention_name>
    <description>Six injections of DV-601 administered over a period of 12 weeks.</description>
    <arm_group_label>DV-601</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.</description>
    <arm_group_label>DV-601</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 18 to 65 years of age.

          -  Signed informed consent.

          -  Diagnosis of CHB and candidates for therapy

          -  Normal renal function

          -  Women of childbearing potential must have a serum negative pregnancy test at
             screening. Women of childbearing potential and males whose sexual partners are of
             childbearing potential must agree to use dual methods of contraception.

        Exclusion Criteria:

          -  Liver disease other than CHB

          -  Documented co-infection with hepatitis A virus (HAV), hepatitis C virus (HCV), or HIV

          -  Previous therapy with interferon alpha.

          -  Any other antiviral therapy for chronic hepatitis B within the previous 3 months prior
             to Screening Visit.

          -  Immunosuppressive treatment (e.g. chemotherapy, high-dose of steroids) within 6 months
             of Screening Visit.

          -  Evidence of cirrhosis

          -  Child-Turcotte-Pugh (CTP) score ≥ 7, either currently or at any occasion in the past

          -  Clinically significant acute or chronic illnesses, such as autoimmune diseases,
             collagen vascular disease, immune deficiencies, active or uncontrolled infections,
             etc. as determined by the investigator and documented in medical history.

          -  Malignancy other than curatively treated, superficial skin cancer or carcinoma in situ
             of the cervix.

          -  Participation in any experimental protocol or therapy within 28 days prior to the
             Screening Visit.

          -  Current substance or alcohol abuse that in the opinion of the investigator would
             interfere with compliance or with interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Collegium Medicum Uniwersytet im. Mikołaja Kopernika</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Wojewódzki Szpital Zespolony</name>
      <address>
        <city>Szczecin</city>
        <zip>71-455</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zakaźny</name>
      <address>
        <city>Warsaw</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Badan Klinicznych</name>
      <address>
        <city>Wrocław</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DV-601</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>entecavir</keyword>
  <keyword>therapeutic vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>a/o August 2016, decision is still pending.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

